Aurobindo Pharma Limited (NSE:AUROPHARMA)
India · Delayed Price · Currency is INR 1,433.70
+7.30 (0.51%)
Jun 1, 2026, 3:29 PM IST
Aurobindo Pharma Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Aurobindo Pharma stock has a consensus rating of "Buy" and an average price target of ₹1,512. The average 1-year stock price forecast is 5.46% higher than the current stock price, while the lowest is ₹1,020 (-28.86%) and the highest is ₹1,785 (+24.50%).
Price Target: ₹1,512 (+5.46%)
Analyst Consensus: Buy
* Price targets were last updated on Feb 15, 2026.
Analyst Ratings
The average analyst rating for Aurobindo Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 17 | 15 | 14 | 15 | 15 |
| Buy | 5 | 6 | 6 | 6 | 6 | 5 |
| Hold | 0 | 0 | 0 | 1 | 1 | 3 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 3 | 3 | 3 | 2 | 2 | 2 |
| Total | 28 | 28 | 26 | 25 | 26 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst ICICI Securities No rating | ICICI Securities | Buy Maintains ₹1,425 | Buy | Maintains | ₹1,425 | -0.61% | Feb 15, 2026 |
Unknown Analyst Axis Direct No rating | Axis Direct | Buy Maintains ₹1,345 | Buy | Maintains | ₹1,345 | -6.19% | Feb 11, 2026 |
Unknown Analyst Motilal Oswal No rating | Motilal Oswal | Buy Maintains ₹1,430 | Buy | Maintains | ₹1,430 | -0.26% | Dec 3, 2025 |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. The data is sourced from Wall Street analysts. Data sources.